Literature DB >> 2692872

The clinical significance of serum high density lipoproteins.

J J Frohlich1, P H Pritchard.   

Abstract

Serum high density lipoproteins (HDL) are a protective factor against atherosclerosis. Many epidemiological studies show a strong inverse relationship between serum HDL-cholesterol (HDL-C) and the likelihood of developing coronary artery disease (CAD). HDL-C levels appear to be a stronger predictive factor for CAD than serum total or low density lipoprotein cholesterol (LDL-C) levels. In the presence of high HDL-C levels, the development of CAD is unlikely even in persons with increased total or LDL-C. Conversely, subjects with low serum levels of HDL-C are at increased risk even if their total and LDL-C is within the "desirable" range. A number of studies have also shown that increasing HDL-C levels is associated with both primary and secondary prevention of atherosclerosis. HDL-C levels should be estimated in individuals with family and/or personal history of premature atherosclerosis, even if they have normal total cholesterol. Only the current problems with the accuracy and precision of the serum HDL-C assay prevent it from being the single most important test for assessment of the lipid risk factors for CAD. The most frequent causes of low HDL-C are smoking, obesity, and hypertriglyceridemia. Treatment of low HDL-C includes removal of these factors, and if this is ineffective, use of drugs. Gemfibrozil and niacin are most effective in raising serum HDL-C, although a number of other medications can markedly improve the total:HDL-C ratio.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2692872     DOI: 10.1016/s0009-9120(89)80091-8

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

1.  Hypoalphalipoproteinemia.

Authors:  J J Frohlich
Journal:  CMAJ       Date:  1992-12-15       Impact factor: 8.262

2.  Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses.

Authors:  E M Rubin; B Y Ishida; S M Clift; R M Krauss
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

Review 3.  High-density lipoprotein/apolipoprotein A-I infusion therapy.

Authors:  Jean-Claude Tardif; Therese Heinonen; Stephane Noble
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

4.  Effect of caffeine on the risk of coronary heart disease- A re-evaluation.

Authors:  J O Adebayo; A O Akinyinka; G A Odewole; J I Okwusidi
Journal:  Indian J Clin Biochem       Date:  2007-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.